Liewei Wang

15.7k total citations · 2 hit papers
233 papers, 8.7k citations indexed

About

Liewei Wang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Liewei Wang has authored 233 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 61 papers in Cancer Research and 59 papers in Oncology. Recurrent topics in Liewei Wang's work include Cancer Genomics and Diagnostics (31 papers), Pharmacogenetics and Drug Metabolism (24 papers) and Estrogen and related hormone effects (22 papers). Liewei Wang is often cited by papers focused on Cancer Genomics and Diagnostics (31 papers), Pharmacogenetics and Drug Metabolism (24 papers) and Estrogen and related hormone effects (22 papers). Liewei Wang collaborates with scholars based in United States, China and Japan. Liewei Wang's co-authors include Richard M. Weinshilboum, Krishna R. Kalari, Zhenkun Lou, Gregory D. Jenkins, Brooke L. Fridley, Nifang Niu, Howard L. McLeod, Liang Li, Jia Yu and André Terzic and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Liewei Wang

226 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt

2009 568 citations Liang Li, Brooke L. Fridley et al. profile →
Genomics and Drug Response

2011 390 citations Liewei Wang, Richard M. Weinshilboum et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liewei Wang United States	48	4.7k	2.0k	1.6k	1.5k	958	233	8.7k
Julia Stingl Germany	46	5.0k 1.1×	5.6k 2.9×	1.8k 1.1×	1.5k 1.1×	1.8k 1.8×	210	11.9k
Jae Bum Kim South Korea	74	10.1k 2.2×	1.3k 0.6×	2.4k 1.5×	1.1k 0.7×	625 0.7×	255	20.6k
Shun Ishibashi Japan	67	6.6k 1.4×	1.3k 0.7×	2.3k 1.4×	880 0.6×	339 0.4×	360	17.2k
Ming‐Feng Hou Taiwan	52	4.5k 1.0×	2.7k 1.4×	2.4k 1.5×	616 0.4×	337 0.4×	410	10.4k
Marilyn Safran Israel	25	5.4k 1.1×	546 0.3×	1.3k 0.8×	1.3k 0.9×	854 0.9×	32	8.8k
Ali Canbay Germany	57	3.8k 0.8×	1.1k 0.6×	836 0.5×	424 0.3×	1.2k 1.2×	387	14.7k
Brooke L. Fridley United States	37	2.6k 0.6×	1.1k 0.6×	1.0k 0.6×	1.0k 0.7×	247 0.3×	221	5.1k
Marina Sirota United States	37	4.2k 0.9×	787 0.4×	1.1k 0.7×	1.3k 0.9×	175 0.2×	141	7.9k
Qing Li China	52	6.1k 1.3×	2.1k 1.1×	1.9k 1.2×	677 0.5×	152 0.2×	300	10.2k
Erwin P. Böttinger United States	63	9.6k 2.0×	2.9k 1.5×	2.0k 1.2×	1.8k 1.3×	290 0.3×	165	18.3k

Countries citing papers authored by Liewei Wang

Since Specialization

Citations

This map shows the geographic impact of Liewei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liewei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liewei Wang more than expected).

Fields of papers citing papers by Liewei Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liewei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liewei Wang. The network helps show where Liewei Wang may publish in the future.

Co-authorship network of co-authors of Liewei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Liewei Wang. A scholar is included among the top collaborators of Liewei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liewei Wang. Liewei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geist, Felix, Xiaojia Tang, Krishna R. Kalari, et al.. (2024). Identification of a Notch transcriptomic signature for breast cancer. Breast Cancer Research. 26(1). 4–4. 4 indexed citations

Tang, Xiaojia, Kevin J. Thompson, Krishna R. Kalari, et al.. (2023). Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors. Breast Cancer Research. 25(1). 57–57. 2 indexed citations

Sicotte, Hugues, Krishna R. Kalari, Sisi Qin, et al.. (2022). Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Molecular Cancer Research. 20(12). 1739–1750. 9 indexed citations

Yu, Jia, Yongxian Zhuang, Xiaoyang Fan, et al.. (2022). Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. Cancers. 14(17). 4220–4220. 11 indexed citations

Zhou, Qin, Xinyi Tu, Qian Zhu, et al.. (2021). Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer Research. 81(12). 3333–3346. 30 indexed citations

Yu, Jia, Bo Qin, Ann M. Moyer, et al.. (2020). Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research. 30(7). 590–601. 71 indexed citations

Shee, Kevin, Matthew Ung, Nicole A. Traphagen, et al.. (2019). A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. Clinical Cancer Research. 26(1). 159–170. 1 indexed citations

Bhattacharyya, Sudeepa, Matthias Arnold, Duan Liu, et al.. (2019). Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry. 9(1). 173–173. 62 indexed citations

Tu, Xinyi, Mohamed M. Kahila, Qin Zhou, et al.. (2018). ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 17(11). 2462–2472. 71 indexed citations

10.

Vu, Trung Nghia, Quin F. Wills, Krishna R. Kalari, et al.. (2018). Isoform-level gene expression patterns in single-cell RNA-sequencing data. Bioinformatics. 34(14). 2392–2400. 12 indexed citations

11.

Ingle, James N., Fang Xie, Matthew J. Ellis, et al.. (2016). Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76(23). 7012–7023. 43 indexed citations

12.

Liu, Tongzheng, Yuan Fang, Haoxing Zhang, et al.. (2015). HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Research. 76(3). 572–581. 33 indexed citations

13.

Ingle, James N., Mohan Liu, D. Lawrence Wickerham, et al.. (2013). Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery. 3(7). 812–825. 56 indexed citations

14.

Niu, Nifang, Daniel J. Schaid, Ryan Abo, et al.. (2012). Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. SHILAP Revista de lepidopterología. 28 indexed citations

15.

Tan, Xiang-Lin, Ann M. Moyer, Brooke L. Fridley, et al.. (2011). Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy. Clinical Cancer Research. 17(17). 5801–5811. 82 indexed citations

16.

Li, Yafei, Zhifu Sun, Julie M. Cunningham, et al.. (2011). Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy. Clinical Cancer Research. 17(11). 3830–3840. 22 indexed citations

17.

Wang, Liewei, Katarzyna A. Ellsworth, Irene Moon, et al.. (2010). Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors. Cancer Research. 70(1). 319–328. 92 indexed citations

18.

Ji, Yuan, Janet E. Olson, Jianping Zhang, et al.. (2008). Breast Cancer Risk Reduction and Membrane-Bound Catechol O -Methyltransferase Genetic Polymorphisms. Cancer Research. 68(14). 5997–6005. 36 indexed citations

19.

Li, Liang, Brooke L. Fridley, Krishna R. Kalari, et al.. (2008). Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression. Cancer Research. 68(17). 7050–7058. 137 indexed citations

20.

Cynthia, X., Araba A. Adjei, Oreste E. Salavaggione, et al.. (2005). Human Aromatase: Gene Resequencing and Functional Genomics. Cancer Research. 65(23). 11071–11082. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact